CHMP recommends EU approval of Roche’s Ocrevus for children and adolescents with relapsing multiple sclerosis

RegulatorypositiveOcrevusPositive

AI Analysis

Summary

Roche announced that the EMA's CHMP has recommended approval of Ocrevus for pediatric patients aged 10 and older with relapsing multiple sclerosis, following U.S. FDA approval in May 2026. A final European Commission decision is expected in the near future.

Outcome Details

CHMP recommends approval of Ocrevus for pediatric patients with relapsing multiple sclerosis

Importance:7/10

Sentiment:

0.85

EU approvalCHMP recommendationpediatric indicationmultiple sclerosisOcrevusEMA

Related Companies

$RHHBY

Read the original article

Published by GlobeNewswire Pharma on September 18, 2026 10:45 AM

Read Original